I TW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Olivier Potterat, et al.) Art Unit: 1624
U.S. Appln. No. : 10/621,272) Examiner: Not Yet Assigned

Confirmation No.: 3309 U.S. Filing Date: 07/17/2003

Title of Invention: Bicyclic oligopeptides

Attny. Docket No.: 1/1368

Mail Stop Amendment Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

February 2, 2005

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith concerning the subject application is an Information Disclosure Statement (Form 1449A/B) under 37 C.F.R. §§1.56 and 1.97, as more specifically described hereinbelow.

date of a nation	This Statement is being filed: i) within three (3) months of the filing all application other than a continued prosecution application under 33 C.F.R ithin three (3) months of the date of entry of the national stage as set forth in
37 C.F.R. §1.49 action on the m	Of in an international application; iii) before the mailing of a first Office erits; or iv) before the mailing of a first Office action after the filing of a tinued examination under 37 C.F.R. §1.114.
C.F.R. §1.97(b) notice of allows	This Statement is being filed after the time period specified in 37 b, but before the mailing date of: i) a final action under 37 C.F.R. §1.113, ii) an action that otherwise closes the application. This Statement is being accompanied by:

A statement as specified in 37 C.F.R. §1.97(e) [see below]; or
The fee set forth in 37 C.F.R. §1.17(p).

	The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
§1.97(c) l	97(d). This Statement is being filed after the period specified in 37 C.F.R. but on or before payment of the issue fee. This Statement is accompanied by a t as specified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R.
1.	97(e).
co	Each item of information contained in the instant information disclosure attement was first cited in any communication from a foreign patent office in a punterpart foreign application not more than three (3) months prior to the filing of e instant information disclosure statement; or
fo ma in: C.	No item of information contained in the instant information disclosure attement was cited in a communication from a foreign patent office in a counterpart reign application, and, to the knowledge of the person signing this certification after aking reasonable inquiry, no item of information contained in the instant formation disclosure statement was known to any individual designated in 37 F.R. §1.56(c) more than three (3) months prior to the filing of the instant formation disclosure statement.
	The fee set forth in 37 C.F.R. §1.17(p).
	The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
lisclosure counterpa n section	Each item of information contained in the accompanying information e statement was cited in a communication from a foreign patent office in a rt application, which communication was not received by any individual designated 1.56(c) more than thirty (30) days prior to the filing of the accompanying on disclosure statement.

The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,

David A. Dow

Attorney for Applicant(s)

Reg. No. 46,124

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877 Tel: (203) 791-6214 Certificate of Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Amendment Commissioner For Patents

P. O. Box 1450

Alexandria, VA 22313-1450

on February 2, 200\$.

David A. Dow, Reg. No. 46,124

PTO/SB/08a (08-03) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ork Reduction Act of 1995, no persons are required to tion of information unless it contains a valid OMB control number Complete if Known Substitute for form 1449A/PTO Application Number 10/621,272 Filing Date **INFORMATION DISCLOSURE** 07/17/2003 First Named Inventor Olivier Potterat STATEMENT BY APPLICANT

Art Unit

2

(Use as many sheets as necessary)

US-

Examiner Name

Attorney Docket Number

1624

Not Yet Assigned

1/1368 Sheet **U. S. PATENT DOCUMENTS** Examiner Cite **Document Number Publication Date** Pages, Columns, Lines, Where Initials* MM-DD-YYYY Applicant of Cited Document Relevant Passages or Relevant Number-Kind Code^{2 (J known)} Figures Appear ^{US-}4,139,526 A 02-13-1979 Daniel F. Veber US-US-US-US-US-US-US-US-US-US-US-US-US-US-

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ 'Number ⁴ 'Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т ⁶
					344444	
				•••••••	***************************************	L

Examiner	 Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www uspto gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 06/30/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for t	form 1449B/PTO			Complete if Known			
				Application Number	10/621,272		
INFOR	MATION DI	SCLO	SURE	Filing Date	07/17/2003		
STATEMENT BY APPLICANT				First Named Inventor	Olivier Potterat		
				Art Unit	1624		
(Use as many sheets as	necessary,)	Examiner Name	Not Yet Assigned		
Sheet	2	of	2	Attorney Docket Number	1/1368		

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
		JANICE C. PARKER, et al., "Effects of Skyrin, a Receptor-Selective Glucagon Antagonist, in Rat and Human Hepatocytes", Diabetes, Vol. 49, 2079-2086 December 2000, XP-001154854				
		JAMES G. McCORMACK, et al., "Pharmacological Approaches to Inhibit Endogenous Glucose Production as a Means of Anti-diabetic Therapy", Current Pharmaceutical Design, 2001, 7, 1451-1474, XP-001154855				
		K.F.PETERSON, et al., "Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans", Diabetologia (2001) 44:2018-2024, XP-002259423				

			لـــــا			

Evaminar	Date	
Examiner	Date	ł
Signature	Considered	
		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.